Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Tiapamil, Ro 11-1781, a Ca ++ Antagonist

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An improved synthesis of tiapamil 3, Ro 11-1781, N-(3,4-dimethoxyphenethyl)- 2-(3,4-dimethoxyphenyl)-N-methyl- m-dithiane-2-propylamine 1,1,3,3-tetraoxide is described. The structure of the corresponding hydrochloride monohydrate 4, a Ca<sup>++</sup> antagonist has been confirmed by an X-ray crystallographic analysis. Since biotransformation of tiapamil into metabolites 5, 6 and 7 occurs mainly in the close vicinity of the nitrogen atom, compound 8 bearing seven deuterium atoms has been synthesised.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-3588-5
          978-3-318-01756-4
          0008-6312
          1421-9751
          1982
          1982
          07 November 2008
          : 69
          : Suppl 1
          : 26-30
          Affiliations
          Pharmaceutical Research Department, F. Hoffmann-La Roche & Co. Ltd., Basel, Switzerland
          Article
          173536 Cardiology 1982;69:26–30
          10.1159/000173536
          © 1982 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Preclinical Data

          Comments

          Comment on this article